HRP20211034T1 - 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze - Google Patents

2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze Download PDF

Info

Publication number
HRP20211034T1
HRP20211034T1 HRP20211034TT HRP20211034T HRP20211034T1 HR P20211034 T1 HRP20211034 T1 HR P20211034T1 HR P20211034T T HRP20211034T T HR P20211034TT HR P20211034 T HRP20211034 T HR P20211034T HR P20211034 T1 HRP20211034 T1 HR P20211034T1
Authority
HR
Croatia
Prior art keywords
ring
nitrogen
membered
oxygen
sulfur
Prior art date
Application number
HRP20211034TT
Other languages
English (en)
Inventor
Nadia AHMAD
Dean Boyall
Jean-Damien Charrier
Chris Davis
Rebecca Davis
Steven Durrant
Gorka ETXEBARRIA I JARDI
Damien Fraysse
Juan-Miguel Jimenez
David Kay
Ronald Knegtel
Donald MIDDELTON
Michael ODONNELL
Maninder PANESAR
Francoise Pierard
Joanne Pinder
David Shaw
Pierre-Henri Storck
John Studley
Heather Twin
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of HRP20211034T1 publication Critical patent/HRP20211034T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Claims (30)

1. Spoj, koji ima formulu I-B: [image] ili njegova farmaceutski prihvatljiva sol, naznačeno time, u kojem (I): R1 je neovisno odabran od fluoro, kloro ili -C(J1)2CN; J1 je neovisno odabran od H ili C1-2alkila; ili dvije pojave J1, skupa s atomom ugljika za kojeg su vezani, tvore po izboru supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran od H; kloro; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkila; -CN; ili C1-3alifatskog lanca pri čemu se do dvije jedinice metilena iz alifatskog lanca po izboru mogu zamijeniti sa -O-, -NR-, -C(O)- ili -S(O)n; L1 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L1 je po želji supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; L2 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L2 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabranih između kisika, dušika ili sumpora; ili L1 i L2, zajedno s dušikom na koji su vezani, čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; prsten D se neovisno bira između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 7-12-člani potpuno zasićeni ili djelomično nezasićeni biciklički prsten s 1-5 heteroatoma odabrana između kisika, dušika ili sumpora; JG je neovisno odabran između halo; -N (R°) 2; 3-6-eročlanog karbociklila; 3-6-eročlanog heterociklila koji ima 1-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-4alkilni lanac u kojem do dvije metilenske jedinice alkilnog lanca se po izboru zamjenjuju sa -O-, -NR-, -C (O) - ili -S (O)n; svaki JG je po izboru supstituiran s 0-2 pojavljivanja JK, dva pojavljivanja JG na istom atomu, zajedno s atomom kojem su vezani, čine 3-6-eročlani prsten s 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; dvije pojave JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prestenski sustav; JK je 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika, ili sumpora; L3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog sa 1-3 pojavljivanja halo; -CN; ili C1-3alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po želji zamijenjene sa - O-, -NR-, -C (O) - ili -S (O)n; N je 0, 1 ili 2; i R i R° su H ili C1-4alkil; ili: u kojem (II): R1 je neovisno odabran od fluoro, kloro ili -C (J1)2CN; J1 je neovisno odabran između H ili C1-2alkila; ili dva pojavljivanja J1, zajedno s atomom ugljika na koji su vezani, tvore poželji supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkila; -CN; ili C1-3alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; L1 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L1 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlanim ne-aromatskim prstenom koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; L2 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L2 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; ili L1 i L2, zajedno s dušikom na koji su vezani čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; L3 je H; C1-3alifat; ili CN; prsten D je neovisno odabran između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 7-12-eročlani potpuno zasićeni ili djelomično nezasićeni biciklički prsten s 1-5 heteroatoma odabrana između kisika, dušika ili sumpora; JG je neovisno odabran između halo; -CN; -N (R°)2; → O; 3-6-eroeročlani karbociklil; 3-6-eročlani heterociklil koji ima 1-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-4alkilni lanac u kojem do dvije metilenske jedinice alkilnog lanca se po izboru zamjenjuju sa -O-, -NR-, -C (O) - ili -S (O)n; svaki JG je po izboru supstituiran s 0-2 pojavljivanja JK, dva pojavljivanja JG na istom atomu, zajedno s atomom za kojeg su vezani, čine 3-6-eročlani prsten s 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prstenski sustav; JK je 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana od kisika, dušika ili sumpora; n je 0, 1 ili 2; i R i R° su H ili C1-4alkil; ili: u kojem (III): R1 je neovisno odabran između fluoro, kloro ili -C (J1)2CN; J1 je neovisno odabran između H ili C1-2alkila; ili dva pojavljivanja J1, zajedno s atomom ugljika na koji su vezani, tvore po želji supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkil; -CN; ili C1-3alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; L1 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L1 je po želji supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlanim ne-aromatskim prstenom koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; L2 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L2 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; ili L1 i L2, zajedno s dušikom na koji su vezani, čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; prsten D se neovisno bira između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 7-12-eročlanog potpuno zasićenog ili djelomično nezasićenog bicikličkog prstena koji ima 1-5 heteroatoma odabrana između kisika, dušika ili sumpora; JG je neovisno odabran između halo; -CN; -N (R°)2; 3-6-eročlanog karbociklila; 3-6-eročlanog heterociklila koji ima od 1-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-4alkilnog lanca pri čemu gore navedene do dvije metilenske jedinice alkilnog lanca se po izboru zamjenjuju sa -O-, -NR-, -C (O) - ili -S(O)n; svaki JG je po želji supstituiran s 0-2 pojavljivanja JK, dva pojavljivanja JG na istom atomu, zajedno s atomom kojem su pridruženi, tvore 3-6-eročlani prsten s 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prestenski sustav; JK je 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika, ili sumpora; n je 0, 1 ili 2; i R i R° su H ili C1-4alkil; ili: u kojem (IV): R1 je neovisno odabran između fluoro, kloro ili -C(J1)2CN; J1 je neovisno odabran između H ili C1-2alkila; ili dva pojavljivanja J1, zajedno s atomom ugljika na koji su vezani, tvore po izboru supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkila; -CN; ili C1-3alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C(O) - ili -S(O)n; L1 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene s -O-, -NR-, -C(O) - ili -S(O)n; svaki L1 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; L2 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene s -O-, -NR-, -C(O)- ili -S(O)n; svaki L2 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; ili L1 i L2, zajedno s dušikom na koji su vezani, čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; prsten D se neovisno bira između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 7-12-eročlanog potpuno zasićenog ili djelomično nezasićenog bicikličkog prstena s 1-5 heteroatoma odabranih između kisika, dušika ili sumpora; JG je neovisno odabran između halo; -N(R°)2; 3-6-eročlanog karbociklila; 3-6-eročlanog heterociklila koji ima 1-2 heteroatoma odabrana između kisika dušika ili sumpora; ili halkilni lanac u kojem do dvije metilenske jedinice alkilnog lanca se po izboru szamjenjuju s -O-, -NR-, -C(O)- ili -S(O)n; svaki JG je po izboru supstituiran s 0-2 pojavljivanja JK, dva pojavljivanja JG na istom atomu, zajedno s atomom kojem su pridruženi, čine 3-6-eročlani prsten s 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prestenski sustav; JK je 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana od kisika, dušika ili sumpora; n je 0, 1 ili 2; i R i R° su H ili C1-4alkil; ili: u kojem (V): R1 je neovisno odabran između fluoro, kloro ili -C (J1)2CN; J1 je neovisno odabran između H ili C1-2alkila; ili dva pojavljivanja J1, zajedno s atomom ugljika na koji su vezani, tvore po želji supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkil; ili -CN; L1 je po izboru supstituirani C1-6alifat; L2 je po izboru supstituirani C1-6alifat; ili L1 i L2, zajedno s dušikom na koji su vezani, čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; prsten D je neovisno odabran između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 8-12-eročlanog potpuno zasićenog ili djelomično nezasićenog bicikličkog prstena s 0-5 heteroatoma odabrana između kisika, dušika ili sumpora; JG je neovisno odabran između C1-4alkila, -N (R°)2 ili 3-5-eročlanog karbociklila; ili dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prstenski sustav; i R° je H ili C1-4alkil.
2. Spoj u skladu s bilo kojim od patentnih zahtjeva 1(I) do 1(IV), naznačeno time, u kojem je (I) R1 fluoro; ili: u kojem je (II) R1 -CH2CN; ili: u kojem je (III) R1 kloro.
3. Spoj u skladu s patentnim zahtjevom 1 do 2(II), naznačeno time, što je R3 neovisno odabran od H, kloro, fluoro, ciklopropila ili C1-4alkila.
4. Spoj u skladu s patentnim zahtjevom 3, naznačeno time, što je (I) R3 neovisno odabran od H, kloro ili fluoro; ili: u kojem je (II) R3 H; ili: u kojem je (III) R3 kloro; ili: u kojem je (IV) R3 fluoro.
5. Spoj u skladu s patentnim zahtjevom 4, naznačeno time, što su L1 i L2 H; -(C1-3alkil)O(C1-2alkil); -(C1-3alkil)N(C1-2alkil)2; C1-4alkil; azetidinil; piperidinil; oksitanil ili pirolidinil.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačeno time, što L1 and L2 zajedno s dušikom za kojeg su vezani, tvore prsten D.
7. Spoj u skladu s patentnim zahtjevom 6, naznačeno time, što je prsten D 3-7-eročlani heterociklički prsten koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora.
8. Spoj u skladu s patentnim zahtjevom 7, naznačeno time, što je (I) prsten D neovisno odabran između piperazinila, piperidinila, morfolinila, tetrahidropiranila, azetidinila, pirolidinila ili 1,4-diazepanila; po izboru gdje je prsten D piperazinil, piperidinil, 1,4-diazepanil, pirolidinil ili azetidinil; po izboru pri čemu je prsten D piperazinil ili piperidinil; ili: gdje je (II) prsten D 8-12-eročlani potpuno zasićeni ili djelomično nezasićeni biciklički prsten koji ima 0-5 heteroatoma odabrana između kisika, dušika ili sumpora; po izboru gdje je prsten D oktahidropirolo[1,2-a] pirazin ili oktahidropirolo [3,4-c] pirol.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 7 i 8, naznačeno time, što JG je halo, C1-4alkil, -O (C1-3alkil), C3-6cikloalkil, 3-6-eročlani heterociklil, -NH (C1-3alkil), -OH ili -N (C1-4alkil)2; po izboru gdje JG je metil, -N(C1-4alkil)2, etil, -O(C1-3alkil), ciklopropil, oksetanil, ciklobutil, pirolidinil, piperidinil ili azetidinil; po izboru pri čemu je JG metal, -O (C1-3alkil), oksetanil, pirolidinil, piperidinil ili azetidinil; po izboru pri čemu je JG metil.
10. Spoj u skladu s patentnim zahtjevom 8, naznačeno time, što dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prstenski sustav; proizvoljno pri čemu je premošteni prstenski sustav 1,4-diazabiciklo[3.2.2]nonan, 1,4-diazabiciklo[3.2.1] oktan ili 2,5-diazabiciklo [2.2.1] heptan.
11. Spojevi u skladu s bilo kojim patentnim zahtjevom 7 i 8 (I), naznačeno time, što dva pojavljivanja JG na istom atomu, zajedno s atomom kojem su pridruženi, tvore 3-6-eročlani prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; po izboru pri čemu se prsten koji nastaje dvjema pojavama JG na istom atomu bira između oksetanila ili ciklopropila.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačeno time, što je neovisno odabran između: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] ili odabran od: [image] [image] ili njegova farmaceutski prihvatljiva sol.
13. Farmaceutski pripravak, naznačeno time, što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12 i farmaceutski prihvatljiv nosač.
14. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačeno time, što se koristi u liječenju karcinoma kod pacijenta.
15. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, koji se koristi u skladu s patentnim zahtjevom 14, naznačeno time, što uporaba nadalje obuhvaća davanje navedenom pacijentu dodatnog terapijskog sredstva neovisno odabranog između sredstva koje oštećuje DNA; pri čemu je navedeno dodatno terapijsko sredstvo prikladno za bolest koja se liječi; i navedeno dodatno terapijsko sredstvo daje se zajedno sa rečenim spojem u obliku jednog doziranja ili odvojeno od rečenog spoja kao dio višestrukog oblika doziranja; po izboru: pri čemu je (I) spomenuto sredstvo koje oštećuje DNA odabrano liječenjem kemoterapijom ili zračenjem; po izboru gdje je sredstvo za oštećenje DNA sredstvo za alkiliranje odabrano od Temozolomida; ili: u kojem je (II) navedeno sredstvo za oštećivanje DNA neovisno odabrano između ionizirajućeg zračenja, radiomimetičkog neokarzinostatina, platinirajućeg sredstva, inhibitora Topo I, inhibitora Topo II, antimetabolita, alkilirajućeg sredstva, alkil sulfonata ili antibiotika; po izboru pri čemu je (i) navedeno sredstvo za oštećivanje DNA neovisno odabrano između ionizirajućeg zračenja, sredstva za platinizaciju, inhibitora Topo I, inhibitora Topo II ili antibiotika; ili: pri čemu je (ii) navedeno sredstvo za oštećivanje DNA neovisno odabrano između ionizirajućeg zračenja, sredstva za platiniranje, inhibitora Topo I, inhibitora Topo II, antimetabolita, sredstva za alkiliranje ili alkil sulfonati; po izboru: pri čemu (a) je navedeno sredstvo za platiniranje neovisno odabrano između Cisplatina, Oksaliplatina, Karboplatina, Nedaplatina, Lobaplatina, Triplatin tetranitrata, pikoplatina, satraplatina, ProLindaca i Aroplatina; navedeni inhibitor Topo I odabran je između Camptothecina, Topotecana, Irinotecan / SN38, Rubitecana i Belotecana; navedeni inhibitor Topo II odabran je između Etopozida, Daunorubicina, Doksorubicina, Aclarubicina, Epirubicina, Idarubicina, Amrubicina, Pirarubicina, Valrubicina, Zorubicina i Tenipozida; navedeni antimetabolit je odabran između Aminopterina, Metotreksata, Pemetrekseda, Raltitrekseda, Pentostatina, Kladribina, Klofarabina, Fludarabina, Tioguanina, Merkaptopurina, Fluorouracila, Kapecitabina, Tegafura, Carmofura, Floxuridinacita, Citridekitara, Gemidrata, Klorafurina navedeno alkilirajuće sredstvo odabrano je iz mehloretamina, ciklofosfamida, ifosfamida, trofosfamida, klorambucila, melfalana, prednimustina, bendamustina, uramustina, estramustina, karmustina, Lomustina, Semustina, Fotemustina, Nimustina, Treptomansulfana, Ranimustfanola, Ranimustfan Triazikiona, Trietilenmelamina, Procarbazina, Dacarbazina, Temozolomida, Altretamina, Mitobronitola, Actinomycina, Bleomycina, Mitomycina i Plicamycina; po izboru: pri čemu (aa) navedeno sredstvo za platiniranje je neovisno odabrano između Cisplatina, Oksaliplatina, Karboplatina, Nedaplatina ili Satraplatina; navedeni inhibitor Topo I odabran je između kamptotecina, topotekana, irinotekana / SN38, rubitekana; spomenuti inhibitor Topo II odabran je između Etopozida; navedeni antimetabolit je odabran između metotreksata, pemetrekseda, tioguanina, fludarabina, kladribina, citarabina, gemcitabina, 6-merkaptopurina ili 5-fluorouracila; spomenuto sredstvo za alkiliranje odabire se između dušične gorušice, nitroso-uree, triazena, alkil sulfonata, prokarbazina ili aziridina; a spomenuti antibiotik odabran je iz obitelji Hydroxyurea, Anthracyclines, Anthracenediones ili Streptomyces; ili: pri čemu se (bb) navedeno sredstvo za oštećenje DNA neovisno bira između sredstva za platiniranje ili ionizirajućeg zračenja; proizvoljno gdje je dodatno terapijsko sredstvo Gemcitabin a tumor je karcinom gušterače; ili: pri čemu je (cc) kemoradijacija gemcitabin i zračenje; ili: pri čemu (b) je antimetabolit Gemcitabin; ili: pri čemu (c) sredstvo koje oštećuje DNA je ionizirajuće zračenje; ili: pri čemu (d) sredstvo za oštećenje DNA je sredstvo za platiniranje neovisno odabrano između Cisplatina ili Carboplatina;ili: pri čemu (e) sredstvo koje oštećuje DNA je inhibitor Topo II odabran između Etopozida; ili: pri čemu (f) sredstvo za oštećivanje DNA neovisno se bira između jednog ili više od sljedećeg: Cisplatin, Carboplatin, Gemcitabin, etopozida, temozolomida ili ionizirajuće zračenje; po izboru pri čemu su dodatna terapijska sredstva odabrana između jednog ili više od sljedećeg: Gemcitabin, Cisplatin ili Carboplatin i etopozid.
16. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim patentnim zahtjevom od 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, koji se koristi u skladu s patentnim zahtjevom 14 ili patentnim zahtjevom 15, naznačeno time, što je navedeni karcinom čvrsti tumor odabran od sljedećih karcinoma: oralno: usna šupljina, usne, jezik, usta, ždrijelo; srčani: sarkom (angiosarkom, fibrosarkom, rabdomiosarkom, liposarkom), miksom, rabdomiom, fibrom, lipom i teratom; pluća: bronhogeni karcinom (skvamozni ili epidermoidni, nediferencirane male stanice, nediferencirane velike stanice, adenokarcinom), alveolarni (bronhiolarni) karcinom, bronhijalni adenom, sarkom, limfom, hondromatozni hamartom, mezoteliom; gastrointestinalni: jednjak (skvamozni karcinom, grkljan, adenokarcinom, leiomiosarkom, limfom), želudac (karcinom, limfom, leiomiosarkom), gušterača (duktalni adenokarcinom, inzulin, glukagonom, gastrinom, karcinoidni tumori, tanki čvor, vipoma karcinom, limfom, karcinoidni tumori, Karposijev sarkom, leiomiom, hemangiom, lipom, neurofibroma, fibrom), crijevo ili debelo crijevo (adenokarcinom, tubularni adenom, vilozni adenom, hamartom, leiomiom), debelo crijevo, debelo crijevo-rektum, kolorektalni, rectum; genitourinarni trakt: bubreg (adenokarcinom, Wilmov tumor [nefroblastom], limfom), mokraćni mjehur i uretra (karcinom skvamoznih stanica, karcinom prijelaznih stanica, adenokarcinom), prostata (adenokarcinom, sarkom), testisi (seminom, teratom, embrionalni karcinom, teratokarcinom , horiokarcinom, sarkom, karcinom intersticijskih stanica, fibroma, fibroadenom, adenomatoidni tumori, lipomi); jetra: hepatom (hepatocelularni karcinom), kolangiokarcinom, hepatoblastom, angiosarkom, hepatocelularni adenom, hemangiom, bilijarni prolazi; Kosti: osteogeni sarkom (osteosarkom), fibrosarkom, maligni fibrozni histiocitom, hondrosarkom, Ewingov sarkom, maligni limfom (sarkom retikulumskih stanica), multipli mijelom, kordom malignog tumora divovskih stanica, osteokronfroma (osteokartilagični kostomandomagijski kostondomagijski kostomandomagijski kosto-bronhomagijski kosto-bronhomagijski kosto-bronhomagijski kosto-bronhomagijski kosto-magni kostoni bronhomani kosti tumori osteoma i divovskih stanica; živčani sustav: lubanja (osteom, hemangiom, granulom, ksantom, osteitis deformans), moždane ovojnice (meningioma, meningiosarkom, gliomatoza), mozak (astrocitom, meduloblastom, gliom, ependimom, germinom [pinealoma], glioblaligoma genomblastomoma multiformni glioblastomahnom, glioblastomahni multiform kongenitalni tumori), neurofibrom leđne moždine, meningiom, gliom, sarkom); ginekološki / ženski: maternica (karcinom endometrija), cerviks (karcinom vrata maternice, predtumorska cervikalna displazija), jajnici (karcinom jajnika [serozni cistadenokarcinom, mucinozni cistadenokarcinom, neklasificirani karcinom], tumori granulosatekalnih stanica, tumori Sertoli-Leydigoma, maligni tumori ćelija teratom), vulve (karcinom skvamoznih stanica, intraepitelna karcinom, adenokarcinom, fibrosarkom, melanom), vaginu (karcinom jasno stanica, karcinom skvamoznih stanica, botrioid sarkoma (embrionalni rabdomiosarkoma), jajovodi (karcinom), dojke, kože: maligni melanom, bazalni stanični karcinom, skvamozni karcinom, Karposijev sarkom, keratoakantom, molsni displastični nevusi, lipomi, angiomi, dermatofibromi, keloidi, psorijaza, štitnjača: papilarni karcinom štitnjače, folikularni karcinom štitnjače; tip 2B, obiteljski medularni karcinom štitnjače, feokromocitom, paragangliom i nadbubrežna glava nds: neuroblastoma: po izboru: pri čemu je spomenuti tumor odabran od karcinoma pluća ili gušterače; po izboru: pri čemu je spomenuti tumor karcinom pluća; proizvoljno: pri čemu je karcinom pluća ne-malih stanica ili karcinom pluća malih stanica; proizvoljno: pri čemu je (I) karcinom pluća malih stanica, a dodatna terapijska sredstva su cisplatin i etopozid; ili pri čemu (II) je karcinom pluća ne-malih stanica, a dodatna terapijska sredstva su gemcitabin i cisplatin; proizvoljno: pri čemu (i) je rak pluća ne-malih stanica stanični karcinom pluća nemalih stanica; ili: pri čemu (ii) je terapija karcinomom gemcitabin i zračenje.
17. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom zahtjevu 13, namijenjen upotrebi u skladu s patentnim zahtjevom 14 ili patentnim zahtjevom 15, naznačeno time, što je (I) navedeni karcinom odabran od karcinoma pluća, carcinoma glave i vrata, karcinoma gušterače, karcinoma želuca ili mozga; ili: pri čemu je (II) spomenuti karcinom odabran od karcinoma pluća ne-malih stanica, karcinoma pluća malih stanica, karcinoma gušterače, carcinoma žučnog trakta, karcinoma glave i vrata, karcinoma mokraćnog mjehura, karcinoma debelog crijeva, glioblastom, karcinoma jednjaka, karcinoma dojke, hepatocelularnog karcinoma ili karcinoma jajnika; po izboru pri čemu je tumor karcinoma dojke i dodatno terapijsko sredstvo je cisplatin; po izboru pri čemu je tumor trostruko negativni karcinom dojke.
18. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što u kombinaciji s dodatnim terapijskim sredstvom odabranim od Gemcitabina, terapije zračenjem ili zajedno s Gemcitabinom i terapijom zračenjem, služi za uporabu u liječenju raka gušterače.
19. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što se koristi u liječenju koje povećava osjetljivost stanica raka gušterače na terapiju karcinoma odabranu između kemoterapije ili zračenja; po želji: pri čemu je (I) kemoterapija gemcitabin; ili: pri čemu je (II) terapija karcinoma gemcitabin; ili: pri čemu je (III) terapija karcinoma zračenje.
20. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačeno time, što u kombinaciji s Gemcitabinom (100 nM) i / ili zračenjem (6 Gy) se koristi u liječenju koje inhibira fosforilaciju Chk1 (Ser 345) u stanici raka gušterače.
21. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što se koristi u liječenju koje senzibilizira stanice raka gušterače na kemoterapiju u kombinaciji s kemoterapijom.
22. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što se koristi u liječenju koji sadrži (I) radiosenzibilizirajuće hipoksične stanice raka gušterače u kombinaciji s terapijom zračenjem; ili: sadrži (II) senzibilizirajuće hipoksične stanice raka gušterače u kombinaciji s kemoterapijom.
23. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevima 21 ili 22, naznačeno time, što je spomenuta stanica karcinoma PSN-1, MiaPaCa-2 ili PancM stanica karcinoma.
24. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 12, naznačeno time, što se koristi u liječenju koje obuhvaća narušavanje kontrolnih točaka staničnog ciklusa uzrokovanih oštećenjem u kombinaciji s terapijom zračenjem i / ili Gemcitabinom.
25. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 12, naznačeno time, što se koristi u liječenju koje obuhvaća inhibiranje popravka oštećenja DNA rekombinacijom hemoglobina u stanici karcinoma gušterače u kombinaciji s terapijom zračenjem i / ili Gemcitabinom.
26. Spoj ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevima 22 do 25, naznačeno time, što se spoj primjenjuje na stanicu raka gušterače; proizvoljno pri čemu su stanice raka gušterače izvedene iz stanične linije gušterače odabrane između PSN-1, MiaPaCa-2 ili Panc-1.
27. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što se koristi u liječenju koje obuhvaća (I) liječenje karcinoma pluća ne-malih stanica u kombinaciji s jednim ili više sljedećih dodatnih terapijskih sredstava: Cisplatin ili Carboplatin , Etopozid i ionizirajuće zračenje; ili: (II) promicanje stanične smrti u stanicama raka; ili: (III) sprječavanje reparacije stanica od oštećenja DNA; ili: (IV) inhibiranje ATR u biološkom uzorku koji obuhvaća korak dovođenja u kontakt spoja prema bilo kojem od zahtjeva 1do 12 s navedenim biološkim uzorkom; proizvoljno pri čemu je navedeni biološki uzorak stanica; ili: (V) senzibilizaciju stanica na sredstva koji oštećuju DNA.
28. Spoj prema bilo kojem od zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom zahtjevu 13, za uporabu skladu s patentnim zahtjevima 15 do 27, naznačeno time, što je (I) navedena stanica stanica raka koja ima nedostatke u ATM signalnoj kaskadi; po izboru: pri čemu (i) je navedeni nedostatak promijenjeni izraz ili aktivnost ili jedan ili više ili slijedeće: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1 / BRIT1, CTIP ili SMC1; ili: pri čemu je (ii) spomenuti nedostatak promijenjena ekspresija ili aktivnost jednog ili više od sljedećeg: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1 ili H2AX. pri čemu (II) rečeni karcinom, stanica raka, ili stanica ima nedostatak na proteinu za popravak bazne ekscizije; proizvoljno pri čemu proteini za popravak bazne ekscizije su: UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glikozilaze); APE1, APEX2 (AP endonukleaze); LIG1, LIG3 (DNA ligaze I i III); XRCC1 (dodatak LIG3); PNK, PNKP (polinukleotid kinaza i fosfataza); PARP1, PARP2 (poli (ADP-ribozne) polimeraze); PolB, PolG (polimeraze); FEN1 (endonukleaza) ili Aprataxin; po izboru, pri čemu je protein za popravak bazne ekscizije PARP1, PARP2 ili PolB; po izboru pri čemu je protein za popravak bazne ekscizije PARP1 ili PARP2.
29. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, koji se koristi u skladu s patentnim zahtjevima 14 do 27, naznačeno time, što je navedena stanica, tumorska stanica koja eksprimira onkogene koji oštećuju DNA; proizvoljno pri čemu je spomenuta tumorska stanica promijenila ekspresiju ili aktivnost jednog ili više od sljedećeg: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Ciklin E, Ciklin A i Rb.
30. Spoj prema bilo kojem od patentnih zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, koji se koristi u skladu s patentnim zahtjevima 15 do 27, naznačeno time, što se nadalje sastoji od primjene na pacijenta dodatnog terapijskog sredstva u kojem navedeno sredstvo inhibira ili modulira protein za popravak bazne ekscizije; proizvoljno u kojem je protein za popravak bazne ekscizije odabran od UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1, APEX2 (AP endonukleaze); LIG1, LIG3 (DNA ligaze I and III); XRCC1 (dodatak LIG3); PNK, PNKP (polinukleotid kinaza i fosfataza); PARP1, PARP2 (Poli(ADP-Riboza) Polimeraza); PolB, PolG (polimeraze); FEN1 (endonukleaza) ili Aprataksin; po izobru pri čemu je protein za popravak bazne ekscizije odabran između PARP1, PARP2 ili PolB; po izboru, pri čemu je protein za popravak bazne ekscizije odabran između PARP1 ili PARP2; po izboru, pri čemu je navedeno sredstvo odabrano od Olapariba (također poznatog kao AZD2281 ili KU-0059436), Inipariba (također poznatog kao BSI-201 ili SAR240550), Velipariba (također poznatog kao ABT-888), Rucapariba (također poznatog kao PF-01367338 ), CEP-9722, INO-1001, MK-4827, E7016, BMN673 ili AZD2461.
HRP20211034TT 2012-12-07 2021-06-30 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze HRP20211034T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734726P 2012-12-07 2012-12-07
US201361787568P 2013-03-15 2013-03-15
US201361868132P 2013-08-21 2013-08-21
EP18212042.8A EP3486245B1 (en) 2012-12-07 2013-12-06 2-amino-n-(piperidin-1-yl-pyridin-3-yl) pyrazolo[1,5alpha]pyrimidine-3-carboxamid as inhibitor of atr kinase

Publications (1)

Publication Number Publication Date
HRP20211034T1 true HRP20211034T1 (hr) 2021-12-10

Family

ID=49877035

Family Applications (4)

Application Number Title Priority Date Filing Date
HRP20230476TT HRP20230476T1 (hr) 2012-12-07 2013-12-06 Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje bolesti karcinoma
HRP20180859TT HRP20180859T1 (hr) 2012-12-07 2018-05-30 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
HRP20202058TT HRP20202058T1 (hr) 2012-12-07 2020-12-23 Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje karcinoma
HRP20211034TT HRP20211034T1 (hr) 2012-12-07 2021-06-30 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HRP20230476TT HRP20230476T1 (hr) 2012-12-07 2013-12-06 Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje bolesti karcinoma
HRP20180859TT HRP20180859T1 (hr) 2012-12-07 2018-05-30 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
HRP20202058TT HRP20202058T1 (hr) 2012-12-07 2020-12-23 Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje karcinoma

Country Status (30)

Country Link
US (8) US9340546B2 (hr)
EP (5) EP2941432B8 (hr)
JP (2) JP6401709B2 (hr)
KR (1) KR102213986B1 (hr)
CN (4) CN107501274B (hr)
AU (2) AU2013355124B2 (hr)
BR (1) BR112015012454B1 (hr)
CA (1) CA2892608C (hr)
CY (4) CY1120232T1 (hr)
DK (4) DK3418281T3 (hr)
ES (4) ES2669423T3 (hr)
FI (1) FI3808749T3 (hr)
HK (2) HK1209746A1 (hr)
HR (4) HRP20230476T1 (hr)
HU (4) HUE055618T2 (hr)
IL (2) IL239218A0 (hr)
LT (4) LT3486245T (hr)
ME (1) ME03036B (hr)
MX (1) MX368042B (hr)
NZ (2) NZ731337A (hr)
PL (3) PL3808749T3 (hr)
PT (4) PT2941432T (hr)
RS (4) RS64234B1 (hr)
RU (1) RU2689996C2 (hr)
SG (2) SG10201606373XA (hr)
SI (4) SI2941432T1 (hr)
TR (1) TR201807740T4 (hr)
TW (1) TWI618706B (hr)
WO (1) WO2014089379A1 (hr)
ZA (2) ZA201503871B (hr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3354650T (pt) 2008-12-19 2022-06-20 Vertex Pharma Compostos úteis como inibidores da cinase atr
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
IN2014CN02501A (hr) 2011-09-30 2015-06-26 Vertex Pharma
JP2015515478A (ja) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SG10201705662WA (en) 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
JP6543252B2 (ja) 2013-12-06 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ＡＴＲキナーゼ阻害剤として有用な２−アミノ−６−フルオロ−Ｎ−［５−フルオロ−ピリジン−３−イル］ピラゾロ［１，５−ａ］ピリミジン−３−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体
MX2016015874A (es) * 2014-06-05 2017-03-27 Vertex Pharma Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) * 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
CN107108581B (zh) * 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
AU2015342887B2 (en) 2014-11-06 2020-09-10 Bial - R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
CA3000684A1 (en) * 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2017123588A1 (en) 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
RU2018132559A (ru) * 2016-02-16 2020-03-17 Массачусетс Инститьют Оф Текнолоджи Связывающие молекулы для max в качестве модуляторов myc и их применения
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
MX2018012211A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
JP7034935B2 (ja) 2016-04-06 2022-03-14 リソソーマル・セラピューティクス・インコーポレイテッド ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
EP3452455A4 (en) 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
CN109311902B (zh) 2016-05-05 2022-07-15 Bial研发投资股份有限公司 取代的咪唑并[1,2-b]哒嗪、咪唑并[1,5-b]哒嗪、相关化合物及其用途
WO2018083085A1 (en) * 2016-11-02 2018-05-11 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
WO2018153969A1 (en) 2017-02-24 2018-08-30 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with radium-223 salt
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
CN106946890A (zh) * 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
CN111867590B (zh) 2017-07-13 2023-11-17 德州大学系统董事会 Atr激酶的杂环抑制剂
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
WO2019036641A1 (en) 2017-08-17 2019-02-21 Board Of Regents, The University Of Texas System HETEROCYCLIC INHIBITORS OF KINASE ATR
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN107935918A (zh) * 2017-11-15 2018-04-20 山东潍坊润丰化工股份有限公司 一种百草枯的制备方法
JP7402159B2 (ja) 2017-11-30 2023-12-20 シージェン インコーポレイテッド 薬物リンカー化合物の調製のためのプロセス
US11712440B2 (en) 2017-12-08 2023-08-01 Bayer Aktiengesellschaft Predictive markers for ATR kinase inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN111526889B (zh) * 2017-12-29 2023-06-02 沃泰克斯药物股份有限公司 使用atr抑制剂治疗癌症的方法
WO2019178590A1 (en) 2018-03-16 2019-09-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of atr kinase
WO2020064971A1 (en) 2018-09-26 2020-04-02 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
WO2020078905A1 (en) 2018-10-15 2020-04-23 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
US20230119558A1 (en) * 2020-03-06 2023-04-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Dna damage repair genes in cancer
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
US20230226066A1 (en) 2020-06-18 2023-07-20 Merck Patent Gmbh Compounds for the treatment of viral infections
WO2022002243A1 (zh) * 2020-07-02 2022-01-06 江苏恒瑞医药股份有限公司 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2023116865A1 (zh) * 2021-12-23 2023-06-29 优领医药科技（上海）有限公司 含吡唑类衍生物、其药学上可接受的盐及其制备方法和应用
CN115322143B (zh) * 2022-07-21 2023-07-14 安徽德诺医药股份有限公司 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JP2597917B2 (ja) 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
KR19990008451A (ko) 1995-05-09 1999-01-25 페라스타르크 피라졸로-(1,5ａ)-피리미딘, 그의 제조 방법 및 용도
WO1997043267A1 (en) 1996-05-11 1997-11-20 Kings College London Pyrazines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
RO121272B1 (ro) 1996-07-24 2007-02-28 The Du Pont Merck Pharmaceutical Company Azolotriazine şi pirimidine
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JPH10218881A (ja) 1997-02-03 1998-08-18 Pola Chem Ind Inc 新規なピロロピラゾロピリミジン誘導体
GB2323861B (en) 1997-02-05 2001-06-20 Sector Exhibiting Systems Artificial wall structure
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
CN1146561C (zh) 1998-07-16 2004-04-21 盐野义制药株式会社 具有抗肿瘤活性的嘧啶衍生物
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2001302666A (ja) 1999-09-21 2001-10-31 Nissan Chem Ind Ltd アゾール縮合ヘテロ環アニライド化合物及び除草剤
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE60037905T2 (de) 1999-12-17 2009-01-29 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazin-basierte hemmer der glycogen-synthase-kinase 3
WO2001092257A1 (en) 2000-05-26 2001-12-06 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US6420637B1 (en) 2001-01-29 2002-07-16 Asgrow Seed Company L.L.C. Plants and seeds of corn variety I389972
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
AU2002305450A1 (en) 2001-05-08 2002-11-18 Yale University Proteomimetic compounds and methods
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
WO2003037900A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
EP1446387B1 (en) 2001-11-21 2009-11-04 Pharmacia & Upjohn Company LLC Substituted aryl 1,4-pyrazine derivatives
CA2475633C (en) 2002-02-06 2013-04-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
CN101450934B (zh) 2002-03-13 2012-10-10 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
JP4414881B2 (ja) 2002-05-31 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾール化合物およびこれを含んでなる医薬組成物
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
MXPA05002570A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TW200413377A (en) 2002-09-04 2004-08-01 Schering Corp Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497544C (en) 2002-09-04 2010-11-02 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
KR101088922B1 (ko) 2002-09-04 2011-12-01 파마코페이아, 엘엘씨. 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
ES2401330T3 (es) 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
CA2516824A1 (en) 2003-02-28 2004-09-10 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
MXPA05009245A (es) 2003-03-11 2005-10-19 Pfizer Prod Inc Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf).
EP1606266A4 (en) 2003-03-21 2008-06-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
CN101468965A (zh) 2003-03-24 2009-07-01 默克公司 联芳基取代的6元杂环钠通道阻滞剂
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
WO2005051301A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
AU2005215379A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
EP1720879A2 (de) 2004-02-25 2006-11-15 Basf Aktiengesellschaft Azolopyrimidin-verbindungen und ihre verwendung zur bekämpfung von schadpilzen
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
PT1812440E (pt) 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
US8003806B2 (en) 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
EP1814883A1 (en) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
ES2368338T3 (es) 2004-12-27 2011-11-16 Novartis Ag Análogos de aminopirazina para el tratamiento del glaucoma y otras enfermedades mediadas por la rho cinasa.
WO2007076360A1 (en) 2005-12-22 2007-07-05 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060156482A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
JP5033119B2 (ja) 2005-04-25 2012-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ阻害剤としての新規アザ複素環化合物
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP5463034B2 (ja) 2005-05-20 2014-04-09 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
EP1931676B1 (en) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US7645762B2 (en) * 2005-10-06 2010-01-12 Schering Corporation Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors
WO2007044441A2 (en) 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
AR055206A1 (es) 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
CA2626789A1 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
CA2630460C (en) 2005-12-01 2013-01-08 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
WO2007066805A1 (ja) 2005-12-09 2007-06-14 Meiji Seika Kaisha, Ltd. リンコマイシン誘導体およびこれを有効成分とする抗菌剤
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
ATE453635T1 (de) 2006-03-22 2010-01-15 Vertex Pharma C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
JP2009531443A (ja) 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
US7700601B2 (en) 2006-03-31 2010-04-20 Schering Corporation Substituted indazoles of formula 1.0 that are kinase inhibitors
EP2027127A1 (en) 2006-05-22 2009-02-25 Shering Corporation Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors
CN101472912A (zh) 2006-06-22 2009-07-01 比奥维特罗姆上市公司 作为mnk激酶抑制剂的吡啶和吡嗪衍生物
US9216963B2 (en) 2006-06-22 2015-12-22 Medibeacon Inc. Pyrazine derivatives with extended conjugation and methods of using the same in optical applications
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
KR101107896B1 (ko) 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체
ZA200902382B (en) 2006-10-19 2010-08-25 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
US8148361B2 (en) 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
US20080176870A1 (en) 2006-11-20 2008-07-24 Bert Nolte Heterobicyclic metalloprotease inhibitors
AR064348A1 (es) 2006-12-15 2009-04-01 Bayer Schering Pharma Ag 3-h-pirazolopiridinas y sales de estas, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
AU2008235089B8 (en) 2007-04-10 2014-04-10 Bayer Intellectual Property Gmbh Insecticidal aryl isoxazoline derivatives
EP2150255A4 (en) 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2014661A1 (de) 2007-06-13 2009-01-14 Bayer CropScience AG Heterocyclisch substituierte Heterocyclyl-carbonsäurederivate
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
EP2157090A4 (en) 2007-06-21 2011-09-07 Taisho Pharmaceutical Co Ltd PYRAZINAMIDVERBINDUNG
CN101784269A (zh) 2007-06-26 2010-07-21 莱西肯医药有限公司 治疗由5-羟色胺介导的疾病和病症的方法
WO2009006580A1 (en) 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
KR101552742B1 (ko) 2007-07-19 2015-09-11 머크 샤프 앤드 돔 코포레이션 단백질 키나제 억제제로서의 헤테로사이클릭 아미드 화합물
AU2008275891B2 (en) 2007-07-19 2013-10-10 H.Lundbeck A/S 5-membered heterocyclic amides and related compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
CA2706946A1 (en) 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2009075790A1 (en) 2007-12-07 2009-06-18 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors for intra-articular application
AU2008343173A1 (en) * 2007-12-19 2009-07-09 Aj Park Pyrazolo [1,5-a] pyrimidines useful as JAK2 inhibitors
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
PT2247592E (pt) 2008-02-25 2011-11-03 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
EP2250172B1 (en) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
BRPI0907928A2 (pt) 2008-02-25 2015-07-28 Hoffmann La Roche Inibidores de pirrolopirazina quinase.
WO2009106445A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
WO2009152087A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
WO2010017047A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
CN102223798A (zh) 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
WO2010048131A1 (en) 2008-10-21 2010-04-29 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors
PE20131197A1 (es) 2008-10-31 2013-11-06 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
RU2011123647A (ru) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, полезные в качестве ингибиторов atr киназы
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
JP5930278B2 (ja) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター Ｍｌｋ阻害剤および使用方法
BRPI0922937A2 (pt) 2008-12-05 2019-09-24 Hoffmann La Roche inibidores de pirrolopirazinil uréia quinase
PT3354650T (pt) 2008-12-19 2022-06-20 Vertex Pharma Compostos úteis como inibidores da cinase atr
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
BRPI1007302A2 (pt) 2009-01-30 2019-09-24 Toyama Chemical Co Ltd composto, inibidor da produção de colágeno, e, agente para tratar doenças associadas com a produção excessiva de colágeno
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
EP2396327A1 (en) 2009-02-11 2011-12-21 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
WO2010111653A2 (en) 2009-03-27 2010-09-30 The Uab Research Foundation Modulating ires-mediated translation
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MX2012000711A (es) 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopirazina de cinasas.
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
CA2782684C (en) 2009-12-04 2018-09-04 Mustapha Haddach Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
BRPI0924512A2 (pt) 2009-12-22 2016-03-01 Intel Corp método e aparelho de fornecimento de execução de aplicativos seguros
SG10201502109VA (en) 2010-03-18 2015-05-28 Pasteur Institut Korea Anti-infective compounds
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
WO2011121096A1 (en) 2010-03-31 2011-10-06 Dkfz Deutsches Krebsforschungszentrum PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS
CA2794428A1 (en) 2010-04-08 2011-10-13 Pfizer Inc. Substituted 3,5-diphenyl-isoxazoline derivatives as insecticides and acaricides
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
EP2569289A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
EP2569286B1 (en) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
CN102947272A (zh) 2010-05-12 2013-02-27 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的2-氨基吡啶衍生物
KR20130083386A (ko) 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
EP2571881A1 (en) 2010-05-20 2013-03-27 F.Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EA201591390A1 (ru) 2010-06-24 2016-06-30 Джилид Сайэнс, Инк. Пиразол[1,5-a]пиримидины для противовирусного лечения
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
MX340490B (es) 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
EP2640386B1 (en) 2010-11-16 2017-01-18 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
DK2649075T3 (en) 2010-12-08 2018-07-30 Us Health SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
ES2583086T3 (es) 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con fluoroalquilo y su uso
CN103502249A (zh) 2011-05-17 2014-01-08 普林斯匹亚生物制药公司 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
IN2014CN02501A (hr) 2011-09-30 2015-06-26 Vertex Pharma
MX2014003796A (es) 2011-09-30 2015-01-16 Vertex Pharma Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
CN104379597A (zh) 2012-04-02 2015-02-25 赛特凯恩蒂克公司 改善膈肌功能的方法
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JP2015515478A (ja) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
EP2855448B1 (en) 2012-05-15 2017-02-08 Cancer Research Technology Ltd 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
US20130317021A1 (en) 2012-05-23 2013-11-28 Savira Pharmaceuticals Gmbh Heterocyclic pyrimidine carbonic acid derivatives which are useful in the treatment, amelioration or prevention of a viral disease
WO2013174930A2 (en) 2012-05-23 2013-11-28 Savira Pharmaceuticals Gmbh 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
US8921388B2 (en) 2012-08-06 2014-12-30 European Molecular Biology Laboratory Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
ES2616432T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de alquenos tricíclicos como inhibidores de la unión del VIH
ES2614034T3 (es) 2012-08-09 2017-05-29 VIIV Healthcare UK (No.5) Limited Derivados de amidina tricíclica como inhibidores de la unión del VIH
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
KR20150044895A (ko) 2012-08-17 2015-04-27 바이엘 크롭사이언스 아게 살곤충제 및 살응애제로서의 아자인돌 카르복실산 아미드 및 아자인돌 티오카르복실산 아미드
BR112015002950A2 (pt) 2012-08-24 2017-08-08 Hoffmann La Roche novos derivados de bicíclico-piridina
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
CA2900335C (en) 2012-10-22 2021-10-26 City Of Hope Synthetic analogs of epipolythiodioxopiperazines and uses thereof
BR112015003160A2 (pt) 2012-10-24 2017-07-04 Becton Dickinson Co corantes de azaindolina - cianina substituídos por hidroxamato e bioconjugados dos mesmos
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US20150158868A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP6543252B2 (ja) 2013-12-06 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ＡＴＲキナーゼ阻害剤として有用な２−アミノ−６−フルオロ−Ｎ−［５−フルオロ−ピリジン−３−イル］ピラゾロ［１，５−ａ］ピリミジン−３−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体
MX2016015874A (es) 2014-06-05 2017-03-27 Vertex Pharma Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr

Also Published As

Publication number Publication date
US11117900B2 (en) 2021-09-14
US9340546B2 (en) 2016-05-17
DK3486245T3 (da) 2021-07-19
AU2018204431B2 (en) 2020-04-02
CN107501274B (zh) 2019-11-22
JP6574859B2 (ja) 2019-09-11
RS62174B1 (sr) 2021-08-31
DK2941432T3 (en) 2018-06-14
TW201434839A (zh) 2014-09-16
TWI618706B (zh) 2018-03-21
LT2941432T (lt) 2018-06-11
TR201807740T4 (tr) 2018-06-21
CN107501275A (zh) 2017-12-22
IL239218A0 (en) 2015-07-30
RU2015127079A (ru) 2017-01-10
HUE052808T2 (hu) 2021-05-28
LT3486245T (lt) 2021-08-25
PL3486245T3 (pl) 2021-11-08
BR112015012454A2 (pt) 2017-07-11
EP3486245A1 (en) 2019-05-22
CN107501275B (zh) 2019-11-22
PL2941432T3 (pl) 2018-09-28
SI2941432T1 (en) 2018-07-31
CA2892608A1 (en) 2014-06-12
ZA201605990B (en) 2019-12-18
SI3486245T1 (sl) 2021-09-30
IL263262B (en) 2019-07-31
DK3418281T3 (da) 2020-12-07
EP3486245B1 (en) 2021-04-28
BR112015012454B1 (pt) 2022-07-05
PT3808749T (pt) 2023-06-07
CY1123702T1 (el) 2022-03-24
US20200140441A1 (en) 2020-05-07
CY1120232T1 (el) 2019-07-10
US20210047333A1 (en) 2021-02-18
US20160347754A1 (en) 2016-12-01
EP2941432B8 (en) 2018-06-27
US20140249157A1 (en) 2014-09-04
LT3808749T (lt) 2023-06-12
US9718827B2 (en) 2017-08-01
EP3418281B1 (en) 2020-09-30
AU2013355124B2 (en) 2018-03-22
HUE061909T2 (hu) 2023-08-28
PT2941432T (pt) 2018-06-01
CY1126044T1 (el) 2023-11-15
EP3808749B1 (en) 2023-03-08
US20180155346A1 (en) 2018-06-07
EP2941432A1 (en) 2015-11-11
US11370798B2 (en) 2022-06-28
HUE055618T2 (hu) 2021-12-28
DK3808749T3 (da) 2023-06-06
MX368042B (es) 2019-09-17
HUE037371T2 (hu) 2018-08-28
CA2892608C (en) 2021-10-19
CN104903325B (zh) 2017-10-20
AU2013355124A1 (en) 2015-06-18
CN107501274A (zh) 2017-12-22
WO2014089379A1 (en) 2014-06-12
ES2669423T3 (es) 2018-05-25
JP2018087213A (ja) 2018-06-07
AU2018204431A1 (en) 2018-07-05
NZ630457A (en) 2017-05-26
HRP20202058T1 (hr) 2021-02-19
ES2842876T3 (es) 2021-07-15
HRP20230476T1 (hr) 2023-07-21
SI3808749T1 (sl) 2023-07-31
US20140163000A1 (en) 2014-06-12
KR20150091171A (ko) 2015-08-07
PL3808749T3 (pl) 2023-07-10
HRP20180859T1 (hr) 2018-07-13
WO2014089379A9 (en) 2015-01-15
SG10201606373XA (en) 2016-09-29
CN104903325A (zh) 2015-09-09
EP3418281A1 (en) 2018-12-26
SI3418281T1 (sl) 2021-02-26
SG11201504467YA (en) 2015-07-30
US20180072735A1 (en) 2018-03-15
JP6401709B2 (ja) 2018-10-10
EP3808749A1 (en) 2021-04-21
US10787452B2 (en) 2020-09-29
CY1124291T1 (el) 2022-07-22
PT3486245T (pt) 2021-07-30
RS64234B1 (sr) 2023-06-30
HK1217190A1 (zh) 2016-12-30
PT3418281T (pt) 2020-12-30
ES2946360T3 (es) 2023-07-17
US10392391B2 (en) 2019-08-27
KR102213986B1 (ko) 2021-02-09
IL263262A (en) 2018-12-31
HK1209746A1 (en) 2016-04-08
RU2689996C2 (ru) 2019-05-30
EP4190786A1 (en) 2023-06-07
ES2884030T3 (es) 2021-12-10
JP2016501244A (ja) 2016-01-18
CN107629059A (zh) 2018-01-26
MX2015007101A (es) 2015-09-29
RS57210B1 (sr) 2018-07-31
ME03036B (me) 2018-10-20
CN107629059B (zh) 2020-07-28
NZ731337A (en) 2019-02-22
US9650381B2 (en) 2017-05-16
LT3418281T (lt) 2021-01-11
RS61319B1 (sr) 2021-02-26
US20230271963A1 (en) 2023-08-31
EP2941432B1 (en) 2018-03-07
ZA201503871B (en) 2016-11-30
FI3808749T3 (fi) 2023-05-31
BR112015012454A8 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
HRP20211034T1 (hr) 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
HRP20191375T1 (hr) Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora
HRP20171915T1 (hr) Spojevi korisni kao inhibitori atr kinaze i kombinirane terapije koje ih koriste
JP2014510151A5 (hr)
JP2015515478A5 (hr)
JP2016512815A5 (hr)
JP2016512816A5 (hr)
JP2016512239A5 (hr)
JP2017186385A5 (hr)
JP2016501244A5 (hr)
HRP20180385T1 (hr) Derivati pirazina korisni kao inhibitori atr kinaze
JP2016540773A5 (hr)
CN108771681B (zh) 作为dna-pk抑制剂的化合物及其氘化衍生物的共晶
JP2013526538A5 (hr)
JP2013526540A5 (hr)
CN103442710B (zh) 检测点激酶1抑制剂和wee1激酶抑制剂的组合
JP2012508260A5 (hr)
JP2013529199A5 (hr)
JP2008530248A5 (hr)
JP2013526541A5 (hr)
RU2011123647A (ru) Соединения, полезные в качестве ингибиторов atr киназы
Chougule et al. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer
RU2007134571A (ru) Комбинация и способы введения терапевтических средств и комбинированной терапии
Ning et al. Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy
ES2796575T3 (es) Composiciones farmacéuticas y su uso